anti-CD66b (human), mAb (ANC3C5)
| Code | Size | Price |
|---|
| ANC-219-020-100ug | 100 ug | £243.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Monoclonal
Antibody Clone: ANC3C5
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Shipping:
BI
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
CEACAM8
EClass:
32160000
Form (Short):
liquid
Formulation:
50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5mg/ml Gentamicin sulfate.
Handling Advice:
Avoid freeze/thaw cycles.
Immunogen:
Recombinant soluble human CD66b.
Long Description:
Monoclonal Antibody. Isotype: Mouse IgG1kappa. Clone: ANC3C5. Applications: ELISA, FACS. 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5mg/ml Gentamicin sulfate. Human CD66b (CEACAM8, CGMb, NCA-95, CD67) is a 95kD member of the Carcinoembryonic Antigen (CEA) group. It is expressed on granulocytes and functions as an adhesion molecule. Similar to the CD66 a, c, and d isoforms, engagement of CD66b on neutrophils causes increased adhesion to endothelial cells. Crosslinking CD66b on neutrophils with antibodies triggers IL-8 release.
Package Type:
Plastic Vial
Product Description:
Human CD66b (CEACAM8, CGMb, NCA-95, CD67) is a 95kD member of the Carcinoembryonic Antigen (CEA) group. It is expressed on granulocytes and functions as an adhesion molecule. Similar to the CD66 a, c, and d isoforms, engagement of CD66b on neutrophils causes increased adhesion to endothelial cells. Crosslinking CD66b on neutrophils with antibodies triggers IL-8 release.
Purity:
>95% (SDS-PAGE)
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at +4°C.
Related Products
| Product Name | Product Code | Supplier | anti-CD66b (human), mAb (ANC1D5) | ANC-217-020 | Ancell | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| anti-CD66b (human), mAb (ANC1D5) (Biotin) | ANC-217-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD66b (human), mAb (ANC3C5) (Biotin) | ANC-219-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD66b (human), mAb (ANC4A4) | ANC-220-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD66b (human), mAb (ANC4A4) (Biotin) | ANC-220-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||